Adial Pharmaceuticals, Inc.
ADIL
$6.44
-$0.21-3.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.40M | 1.57M | 1.27M | 1.24M | 1.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.84M | 2.00M | 1.89M | 1.76M | 1.88M |
| Operating Income | -5.84M | -2.00M | -1.89M | -1.76M | -1.88M |
| Income Before Tax | -51.99M | -2.02M | -2.00M | -1.79M | -1.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.99M | -2.02M | -2.00M | -1.79M | -1.96M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.99M | -2.02M | -2.00M | -1.79M | -1.96M |
| EBIT | -5.84M | -2.00M | -1.89M | -1.76M | -1.88M |
| EBITDA | -5.84M | -2.00M | -1.89M | -1.76M | -1.88M |
| EPS Basic | -11.25 | -1.48 | -1.82 | -2.02 | -4.61 |
| Normalized Basic EPS | 0.03 | -0.92 | -1.14 | -1.26 | -2.88 |
| EPS Diluted | -11.25 | -1.48 | -1.82 | -2.02 | -4.61 |
| Normalized Diluted EPS | 0.03 | -0.92 | -1.14 | -1.26 | -2.88 |
| Average Basic Shares Outstanding | 4.62M | 1.37M | 1.09M | 886.90K | 424.90K |
| Average Diluted Shares Outstanding | 4.62M | 1.37M | 1.09M | 886.90K | 424.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |